Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients
Open Access
- 18 October 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 63 (1), 167-169
- https://doi.org/10.1093/jac/dkn442
Abstract
The aim of the study was to assess the biliary penetration of linezolid and the probabilities of attaining optimal pharmacodynamic exposure against vancomycin-resistant enterococci (VRE) in the bile of liver transplant (LTx) patients who received linezolid for the treatment of multidrug-resistant Gram-positive hospital infections. After at least 2 days of standard 600 mg twice-daily therapy, simultaneous bile and blood samples for linezolid assay were collected from six LTx patients just prior to drug administration to determine trough concentrations (Cmin) at steady-state in both sites. Linezolid concentrations in plasma and in bile were analysed by means of HPLC. Biliary penetration of linezolid was calculated as the ratio between Cmin in bile and in plasma. Optimal theoretical pharmacodynamic exposure of linezolid against VRE in bile was defined as biliary Cmin > MIC90. Cmin of linezolid in bile achieved very high values at steady-state, which were significantly higher than in plasma (median of 21.77 versus 8.08 mg/L, P = 0.021). The very high biliary penetration of linezolid (median value of 1.93; range 1.31–4.83) enabled achievement of optimal theoretical pharmacodynamic exposure against VRE in bile (Cmin > 2 mg/L) on all of the occasions. These preliminary data suggest a potential role for linezolid in the treatment of cholangitis due to VRE in LTx patients. Obviously, further confirmatory data assessing also the AUC/MIC ratio of linezolid in bile are needed.This publication has 14 references indexed in Scilit:
- Infection Control Experience in a Cooperative Care Center for Transplant PatientsInfection Control & Hospital Epidemiology, 2008
- Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countriesDiagnostic Microbiology and Infectious Disease, 2007
- Does Linezolid Inhibit Its Own Metabolism?—Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic PatientsDrug Metabolism and Disposition, 2007
- Antimicrobial therapy for acute cholangitis: Tokyo GuidelinesJournal of Hepato-Biliary-Pancreatic Surgery, 2007
- Infections after Living-Donor Liver TransplantationSurgical Infections, 2006
- Hyperlactacidemia Potentially Due to Linezolid Overexposure in a Liver Transplant RecipientClinical Infectious Diseases, 2006
- Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infectionsJournal of Antimicrobial Chemotherapy, 2003
- Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use ProgrammeClinical Pharmacokinetics, 2003
- In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid)Antimicrobial Agents and Chemotherapy, 2002
- Vancomycin-resistant Enterococci: the clinical effect of a common nosocomial pathogenDiagnostic Microbiology and Infectious Disease, 1999